9th Circ. Denies Rehearing In CTI Contract Suit

Law360, New York (January 8, 2010, 4:18 PM EST) -- A federal appeals court won't budge on its finding that Cell Therapeutics Inc.’s settlement of a qui tam suit should not preclude CTI from seeking contractual indemnification from its reimbursement consultant, a predecessor of Lash Group Inc., for damages as part of the government’s investigation of its leukemia treatment Trisonex.

The U.S. Court of Appeals for the Ninth Circuit on Wednesday denied a petition for panel rehearing and rehearing en banc, requested by Lash, and said no further petitions would be entertained.

The Ninth Circuit revised...
To view the full article, register now.